Rejection

(redirected from Antibody-Mediated Rejection)
Also found in: Dictionary, Thesaurus, Medical, Legal, Financial, Acronyms.

rejection

[ri′jek·shən]
(immunology)
Destruction of a graft by the immune system of the recipient.

What does it mean when you dream about a rejection?

Rejection in a dream may suggest that there are feelings or situations the dreamer wants to be rid of.

References in periodicals archive ?
Pre- and post-operative plasmapheresis results in a dramatic drop in DSA levels, which reduces the risk of hyper-acute rejections and early antibody-mediated rejections.
Antibody-mediated rejection of the lung: a consensus report of the International Society for Heart and Lung Transplantation.
C4d, a complement product of classical pathway (12) (triggered by anti-donor antibody) is used as a durable marker for predicting antibody-mediated rejection.
Banff 2011 meeting report: new concepts in antibody-mediated rejection," American Journal of Transplantation, vol.
The importance of technological advances in laboratory-based testing in assessing the risk of antibody-mediated rejection in renal transplantation is highlighted.
Guidelines for the diagnosis of antibody-mediated rejection in pancreas allografts-updated Banff grading schema.
As C4d-negative antibody-mediated rejection (AMR) was not a recognized entity in 2013; she was only treated with intravenous pulses of methylprednisolone and the creatinine stabilized at 160 [micro]mol/L.
Several monoclonal antibodies (MABs) are being studied to help solve the problem of antibody-mediated rejection.
Nasdaq: ALXN) today announced that researchers are scheduled to present clinical and laboratory research on the role of terminal complement inhibition therapy in kidney transplantation patients at high risk for antibody-mediated rejection (AMR) at the American Transplant Congress, being held May 1 to 5, 2010, in San Diego.
If antibody-mediated rejection persists, plasmapheresis continues until it is treated and adequate allograft function ensues (Padmanabhan et al.
Treatment with sCD83 alone was capable of controlling antibody-mediated rejection and prolonging survival of cardiac allografts by twofold when compared to untreated controls.
Antibody-mediated rejection (AMR) in kidney and heart allografts has been thoroughly investigated and has been shown to be an important cause of acute and chronic rejection.

Full browser ?